REPLICATE BIOSCIENCE
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.
REPLICATE BIOSCIENCE
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2020-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.replicatebioscience.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
46 M USD
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Creyon Bio
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Foresight Diagnostics
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw.
Cultured Decadence
Cultured Decadence creats novel methods to make crustacean products using cell culture and tissue engineering techniques.
Mercy BioAnalytics
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Ocelot Bio
Ocelot Bio brings new treatment options to patients with severe liver disease.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series A - Replicate Bioscience
Apple Tree Partners
Apple Tree Partners investment in Seed Round - Replicate Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-12 | Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors |
Official Site Inspections
http://www.replicatebioscience.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Replicate Bioscience"
Home | Replicate Bioscience
Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas, including infectious disease, oncology, and autoimmune disorders. Improved performance …See details»
About Us | Replicate Bioscience
Guided by our team of srRNA experts and with a customizable library of synthetic srRNA vectors and end-to-end development capabilities at our disposal, we are uniquely positioned to …See details»
Our Science | Replicate Bioscience
Our platform leverages next-generation self-replicating RNA (srRNA) vectors to amplify protein expression and surpass the bold expectations for the field of RNA treatments. srRNA’s self …See details»
Replicate Bioscience - Crunchbase Company Profile
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform. View contacts for Replicate Bioscience to access new leads and connect with decision-makers.See details»
Replicate Bioscience, Inc. | LinkedIn
Replicate Bioscience, Inc. | 2,689 followers on LinkedIn. The Power of RNA Amplified | Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating...See details»
Replicate Bioscience - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Replicate Bioscience. Use the PitchBook Platform to explore the full profile.See details»
ATP Announces $40 Million in Series A Funding for srRNA …
Replicate will use $40 million in committed Series A funding from ATP to advance multiple novel srRNA programs into clinical development.See details»
Curia and Replicate Bioscience Enter Strategic
Jun 9, 2022 · Replicate Bioscience, an ATP company, is designing and delivering srRNA immunotherapies to revolutionize the practice of medicine and improve and save lives. Replicate applies advanced srRNA...See details»
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation ...
Sep 12, 2023 · Replicate's first vaccine product, RBI-4000, is an srRNA vaccine developed to stimulate virus-neutralizing immune responses to rabies for prophylactic use. The Phase 1 trial …See details»
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation ...
Sep 12, 2023 · Replicate’s first vaccine product, RBI-4000, is an srRNA vaccine developed to stimulate virus-neutralizing immune responses to rabies for prophylactic use. The Phase 1 trial …See details»
Replicate Bioscience Presents Positive Data from Phase 1 Trial and ...
May 11, 2024 · Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology, autoimmune …See details»
Replicate Bioscience – 2021 OTC Annual Report
Oct 20, 2021 · Replicate Bioscience is developing RNA-based treatments for cancer using proprietary Synthetic Replicon for gene delivery (SynRGY) technology to deliver the genetic …See details»
Replicate Bioscience Initiates a Phase 1 Trial of its Next ... - BioSpace
Sep 12, 2023 · Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA modalities and expand …See details»
Replicate Bioscience Expands Leadership Team, Appointing …
SAN DIEGO, Calif., July 12, 2022/PRNewswire/ — Replicate Bioscience, a company pioneering self-replicating RNA (srRNA) therapies for use against cancers, immune and inflammatory …See details»
Replicate Bioscience Announces Positive Initial Clinical Results for ...
Feb 14, 2024 · Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today …See details»
Replicate Bioscience Announces Positive Initial Clinical Results for ...
Feb 13, 2024 · SAN DIEGO, Calif., Feb. 14, 2024 – Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of …See details»
Replicate Bioscience Announces Positive Initial Clinical Results for ...
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA …See details»
Replicate Bioscience Announces Positive Initial Clinical Results for ...
Feb 14, 2024 · Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today …See details»
Replicate Bioscience Presents Positive Data from Phase 1 Trial and ...
May 11, 2024 · Replicate Bioscience, an Apple Tree Partners portfolio company, is a clinical-stage company amplifying the power of RNA therapeutics by pioneering its novel self …See details»